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Tigecycline, a new glycylcycline antibiotic, is the 9-t-butyl-glycylamido semisynthe-
tic derivative of tetracycline minocycline (1). Tigecycline is moderately bound to human
plasma proteins, penetrates highly into inflammatory fluid (2) and exhibits high activity
against a broad array of bacteria (3). High intracellular concentrations within polymor-
phonuclear leukocytes (PMNs) were demonstrated after 1 h of incubation (4). Different
antibiotics may have divergent effects on cells of the immune system (5). We had previ-
ously found some, but not all, tetracyclines to influence human PMN receptors and fun-
ctions (6–8). We now studied normal PMNs after incubation with tigecycline to see if the
high intracellular concentrations of this tetracycline derived antibiotic interfered with
phagocytosis-associated surface receptors on PMNs and with the PMN function as mea-
sured by phagocytosis and oxidative burst after incubation with Staphylococcus aureus.
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Tigecycline achieves high intracellular concentrations in
polymorphonuclear leukocytes (PMNs). To evaluate the
effects of tigecycline on human PMNs, PMNs were incu-
bated with tigecycline dilutions (0.1 to 100 mg L–1). Pha-
gocytosis-associated PMN Fcg- and complement receptors
as well as phagocytosis and oxidative burst induced by
Staphylococcus aureus were measured by flow cytometry.
Incubation with tigecycline caused small but significant
decreases in the density of complement receptors CD11b
and CD35 (all concentrations) and Fcg receptors CD16 and
CD32 (high concentrations), but not in the percentages of
receptor-bearing cells, except for small reductions in the
proportions of CD16 positive cells at high concentrations.
Tigecycline had no effect on phagocytosis or oxidative
burst induced by S. aureus. Tigecycline was thus associa-
ted with decreased density of PMN complement and (at
high concentrations) Fcg receptors. Although statistically
significant, the differences were small and did not influ-
ence the PMN function as measured by phagocytosis and
oxidative burst.
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EXPERIMENTAL
Tigecycline
Tigecycline (Wyeth Pharmaceuticals, USA) was dissolved in Dulbecco’s phosphate-
-buffered saline supplemented with glucose and bovine serum albumin (DPBS-GA) and
used the same day.
Cells and incubation
PMNs were obtained from heparinized venous blood of healthy donors. Erythro-
cytes were lysed and the leukocyte fraction was washed twice, resuspended in DPBS-
-GA and adjusted to a concentration of 1.25 ´ 107 nonlymphocytes (PMNs and mono-
cytes) per mL (9). Viability was > 98 % as measured by trypan blue exclusion.
Leukocytes were preincubated for 30 min at 37 °C in different concentrations of ti-
gecycline in DPBS-GA in sterile and nonpyrogenic microtiter plates (Costar® 3790 96 Well
Cell Culture Cluster, Corning, USA) in a temperature-controlled shaker. Control cells were
incubated in DPBS-GA without tigecycline.
Receptor studies
PMNs were marked with the following mouse anti-human monoclonal antibodies
according to the instructions of the manufacturers: CD11b-PE (BD Biosciences, USA),
CD16-PC5, CD32-PE, CD35-FITC, CD64-FITC and isotype controls IgG1-FITC, IgG1-PC5
and IgG2a-PE (Beckman Coulter, UK). Results are presented as mean fluorescence inten-
sity (MFI) in arbitrary units.
Phagocytosis and oxidative burst
S. aureus bacteria (Cowan III, NCTC 8532, National Collection of Type Cultures, UK)
opsonized with pooled human serum were used as targets for phagocytosis and stimuli
for oxidative burst. For phagocytosis, bacteria were labelled with rhodamine green X,
and oxidative burst substrate was dihydrorhodamine 123.
For phagocytosis, leukocytes were preincubated as described. Preopsonized rhod-
amine green X-labelled S. aureus (20 per nonlymphocyte) were added to the leukocyte
wells for 7.5 min. The reaction was stopped by adding 0.2 mL of cold DPBS with 0.02 %
EDTA to each well. The plates were then put on ice for 30 min, diluted 1:5 in DPBS-EDTA
and phagocytosing and non-phagocytosing cells were counted by flow cytometry. The re-
sults are presented as phagocytic index, defined as the percentage of phagocytosing non-
lymphocytes multiplied by the mean number of bacteria per phagocytosing cell.
For oxidative burst quantitation, preopsonized, unlabelled S. aureus (20 per nonlym-
phocyte) and 10 mg mL–1 of dihydrorhodamine 123 were added to each leukocyte well,
the final concentration of dihydrorhodamine being 2 mg mL–1. The resulting conversion
to fluorescent rhodamine was measured by flow cytometry (10). Results are presented in
arbitrary units.
Flow cytometry was performed on a Coulter Epics XL-MCL flow cytometer (Beck-
man Coulter) (10).
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Statistical analysis
Data are presented as mean ± SD. Student’s paired sample t-test (SPSS) was used to
determine the significance of differences.
Ethics
The study was approved by the Regional Committee for Medical Research Ethics,
Western Norway.
RESULTS AND DISCUSSION
CD11b and CD35 density on the cells was reduced with all tigecycline concentra-
tions (Fig. 1). CD16 density was reduced with 100 mg L–1 of tigecycline only (Fig. 2), and
CD32 with 10 and 100 mg L–1 (Fig. 3).
The proportions of PMNs bearing complement (CD11b, CD35) or FcgII (CD32) re-
ceptors were not influenced by incubation with tigecycline and were between 98.9 % and
100.0 % (mean values) for all tigecycline concentrations as well as for the controls. The
proportion of CD16 positive cells was slightly lower (mean 94.4 % without tigecycline),
and decreased to a mean value of 86.8 % with 100 mg L–1 of tigecycline (p < 0.05, data
not shown). No significant differences were found in either of these cases.
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Fig. 1. Density of complement receptors
CD11b (squares) and CD35 (triangles)
after incubation in tigecycline. Bars rep-
resent standard deviations of the means
of 12 samples. Incubation in tigecycline
(all concentrations) was associated with
a significant (*: p < 0.05) reduction of re-
ceptor density. MFI – mean fluorescence
intensity.
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Fig. 2. Density of Fcg receptor III
(CD16) after incubation in tigecycline.
Bars represent standard deviations of
the means of 12 samples. Cells incuba-
ted in 100 mg L–1 of tigecycline showed
a significantly (*: p < 0.05) decreased
receptor expression. MFI – mean fluo-
rescence intensity.
Phagocytosis of S. aureus was not influenced by incubation in 0.1, 1, 10, or 100 mg
L–1 of tigecycline (Fig. 4). Oxidative burst was not affected neither (Fig. 5).
We found incubation of PMNs with tigecycline to be associated with small but sta-
tistically significant decreases in the density of complement and, at high concentrations,
of Fcg receptors on the cells. However, with the exception of a small decrease in the per-
centages of cells bearing the CD16 receptor after incubation in high concentrations of
tigecycline (10 and 100 mg L–1), the proportions of cells bearing these receptors were not
affected, and neither were phagocytosis and oxidative burst. This suggests that tigecy-
cline, at this wide range of concentrations, does not affect human PMN function as mea-
sured by these parameters.
S. aureus are normally phagocytosed via complement receptors. The fact that signifi-
cant decreases in CD11b density on the phagocytes were not associated with attenuated
phagocytosis of S. aureus suggests an inherent over-capacity of this part of the immune
system.
To our knowledge, the effects of tigecycline on PMN function have not been previ-
ously studied. However, tigecycline is a derivative of tetracycline, minocycline, and dele-
terious effects of tetracyclines on PMN phagocytosis have been known for more than
three decades (11). We have previously found diverging effects of different tetracyclines
on PMN functions; while high concentrations of doxycycline and minocycline were
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Fig. 3. Density of Fcg receptor II (CD32) after
incubation in tigecycline. Bars represent stan-
dard deviations of the means of 12 samples.
Cells incubated in 10 and 100 mg L–1 of tige-
cycline showed a significantly (*: p < 0.05) de-
creased receptor expression. MFI – mean flu-
orescence intensity.
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Fig. 4. Phagocytosis of S. aureus without and with
0.1, 1, 10 and 100 mg L–1 of tigecycline. The re-
sults are presented as phagocytic index, defined
as the percentage of phagocytosing nonlympho-
cytes multiplied by the mean number of bacte-
ria per phagocytosing cell. Bars represent stan-
dard deviations of the means of 12 samples. No
significant differences were observed.
found to impair PMN chemiluminescence and glucose oxidation, this was not the case
with oxytetracycline (6). Incubation in doxycycline was also associated with a decreased
percentage of Fcg receptor bearing PMNs and lymphocytes (7), and patients with acute
myocardial infarction receiving doxycycline were found to have reduced PMN activity
(12). However, a decrease in PMN chemiluminescence with increasing concentrations of
doxycycline could not be reproduced using a commercial doxycycline preparation, sug-
gesting that additives may neutralize this effect in some i.v. preparations (8).
CONCLUSIONS
High intracellular concentrations of tigecycline in PMNs (4) may be a therapeutic
advantage (1). While the transport of tigecycline into the cells may be associated with
changes in the density of surface receptors, as suggested by the results of the present
study, with small but significant decreases in the density of complement and Fcg recep-
tors, we found no indication of interference with the antimicrobial function of the cells,
not even at supratherapeutic concentrations of the drug.
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Fig. 5. Oxidative burst induced by S.
aureus without and with 0.1, 1, 10 and
100 mg L–1 of tigecycline. Bars repre-
sent standard deviations of the means
of 12 samples.
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S A @ E T A K
Tigeciklin slabi receptore za polimorfonuklearne leukocite (PMN)
ali ne i njihovu funkciju
ARE NAESS, HRISTINA ANDREEVA i STEINAR SØRNES
Tigeciklin posti`e visoku intracelularnu koncentraciju u polimorfonuklearnim leu-
kocitima (PMN). Da se ispita u~inak tigeciklina na humane PMN, PMN su inkubirani s
razli~itim koncentracijama tigeciklina (0,1 do 100 mg L–1). Proto~nom citometrijom pra-
}eni su s fagocitozom povezani PMN Fcg- i komplementarni receptori, fagocitoza i oksi-
dativno prsnu}e inducirano bakterijom Staphylococcus aureus. Inkubacija s tigeciklinom
utjecala je na malo, ali zna~ajno smanjenje gusto}e komplementarnih receptora CD11b i
CD35 (sve koncentracije) i Fcg receptora CD16 i CD32 (visoke koncentracije), ali ne i na
postotak stanica s receptorom, osim malog smanjenja udjela CD16 pozitivnih stanica pri
visokim koncentracijama. Tigeciklin nije imao u~inak na fagocitozu ni na oksidativno
prsnu}e inducirano bakterijom S. aureus. Zbog toga je tigeciklin povezan samo sa
smanjenjem gusto}e PMN komplementa i u visokim koncentracijama Fcg receptora. Iako
je razlika statisti~ki zna~ajna, bila je mala i nije utjecala na funkciju PMN u pogledu fa-
gocitoze i oksidativnog prsnu}a.
Klju~ne rije~i: tigeciklin, leukocit, fagocitiza, oksidativno prsnu}e
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